1. Home
  2. RMTI vs BEAT Comparison

RMTI vs BEAT Comparison

Compare RMTI & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rockwell Medical Inc.

RMTI

Rockwell Medical Inc.

HOLD

Current Price

$0.84

Market Cap

35.1M

Sector

Health Care

ML Signal

HOLD

BEAT

Heartbeam Inc.

HOLD

Current Price

$2.88

Market Cap

63.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMTI
BEAT
Founded
1994
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
35.1M
63.5M
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
RMTI
BEAT
Price
$0.84
$2.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$2.50
$6.75
AVG Volume (30 Days)
230.8K
37.1M
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$75,577,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$0.54
52 Week High
$2.41
$4.00

Technical Indicators

Market Signals
Indicator
RMTI
BEAT
Relative Strength Index (RSI) 39.39 69.20
Support Level $0.81 $2.50
Resistance Level $0.88 $4.00
Average True Range (ATR) 0.06 0.56
MACD -0.00 0.21
Stochastic Oscillator 19.81 69.16

Price Performance

Historical Comparison
RMTI
BEAT

About RMTI Rockwell Medical Inc.

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Share on Social Networks: